The peptide hormone oxytocin modulates socioemotional behaviour and sexual reproduction via the centrally expressed oxytocin receptor (OTR) across several species. Here, we report the crystal structure of human OTR in complex with retosiban, a non-peptide antagonist developed as an oral drug for the prevention of preterm labour. Our structure reveals insights into the detailed interactions between the G-protein coupled receptor (GPCR) and an OTR-selective antagonist. The observation of an extrahelical cholesterol molecule, binding in an unexpected location between helix IV and V, provides a structural rationale for its allosteric effect and critical influence on OTR function. Furthermore, our structure in combination with experimental data allows the identification of a conserved neurohypophyseal receptor-specific coordination site for Mg 2+ that acts as potent positive allosteric modulator for agonist binding.
Introduction
Across many species, signalling mediated by oxytocin-and vasopressin-related neuropeptides provides a global, biologically conserved organising role in sexual reproduction and social behaviour 1 . In mammals, oxytocin and vasopressin orchestrate their biological role through binding and activation of closely related G protein-coupled receptors (GPCRs), called the oxytocin receptor (OTR) and the vasopressin receptors (V1aR, V1bR and V2R) 2, 3 . The neurohypophyseal peptide hormones oxytocin and vasopressin differ only in two of their nine amino acids, but they are structurally distinct from other neuropeptides in being cyclised through a disulfide bond between two cysteines at positions 1 and 6 of the peptide chain 4, 5 .
Oxytocin has numerous functions and its central neurotransmitter-like action has been shown to widely modulate cognitive effects, regulating the establishment and maintenance of complex social and bonding behaviour 6, 7 , while peripheral activation of OTR is intimately linked to parturition and lactation [8] [9] [10] [11] . Translational neuroscience research suggests that targeted activation of the OTR may have therapeutic potential in the treatment of mental health disorders including autism, Asperger's syndrome, social anxiety disorder and schizophrenia [12] [13] [14] [15] [16] [17] , while OTR antagonism can be of value in the treatment of male sexual disorders, assisted reproductive technologies and spontaneous premature labour [18] [19] [20] . However, to date, the only clinically approved OTR-targeted treatments are peptide-based ligands in obstetrics that have to be delivered through intravenous administration. To induce labour, the endogenous agonist oxytocin is administered 21 , while conversely for the prevention of preterm labour, which is still the leading cause of morbidity and mortality of children under the age of five (https://www.unicef.org/publications/index_103264.html), the antagonist atosiban is clinically approved 22 .
Despite the clear therapeutic potential of targeted intervention within this evolutionarily ancient signalling system, it has so far remained challenging to identify suitable orally available small molecule ligands that display high specificity and potency towards the OTR. Certainly, these issues can be attributed to the lack of any detailed structural information on the OTR (or the closely related vasopressin receptors) and therefore, the absence of a precise understanding of the structural determinants for ligand interaction and selectivity. Furthermore, drug discovery efforts are complicated by the OTR's strong and incompletely understood dependence on allosteric modulators such as cholesterol and magnesium (Mg 2+ ), which were shown to critically influence the interaction between the receptor and extracellular ligands 23, 24 .
Here we report the first crystal structure of OTR, bound to the orally available antagonist retosiban that has been clinically developed as a tocolytic agent to efficiently block the oxytocin-mediated contraction of the smooth muscle in the uterus that occurs during the initiation of preterm labour.
In comparison to other peptidergic GPCRs, the antagonist-bound OTR structure displays an enlarged binding pocket, which is exposed to the extracellular solvent. Specific contacts with the co-crystallised antagonist retosiban are mediated through both polar and hydrophobic interacting residues that are located on opposing hemispheres of the binding cavity. Furthermore, the crystal structure allowed the identification of the binding site for the physiologically essential allosteric cholesterol molecule, which we find to be located in a pocket formed by transmembrane helices IV and V.
Finally, the identification and functional verification of two highly conserved, negatively charged residues at the extracellular tips of transmembrane helices I and II, exclusive within the neurohypophyseal oxytocin/vasopressin receptor family, allows us to postulate a structural rationale for the strong allosteric effect that Mg 2+ exerts on agonist binding affinity. Thus, the OTR structure reported here provides the first detailed structural information on this peculiar neuropeptide-binding GPCR and provides answers to long-standing questions with regard to its allosteric modulation by both a sterol and ions.
Results

Structure Determination
To achieve significant purification yields of functional OTR, two consecutive rounds of directed evolution in Saccharomyces cerevisiae were performed on the human wild-type OTR (wtOTR) 25 . Furthermore, to allow for crystallisation in lipidic cubic phase (LCP), 34 residues (residues R232 to L265) of the third intracellular loop (ICL3) were replaced with the thermostable Pyrococcus abysii glycogen synthase (PGS) domain 26 , 30 residues of the flexible C-terminus (residues 360 to 389) were truncated and residues D153 4.42 and S224 5.62 (Ballesteros and Weinstein numbering denoted in superscript 27 ) were substituted with alanine to increase thermostability. In combination, these modifications resulted in almost unaltered binding affinity for the co-crystallised antagonist retosiban (Supplementary Table 2 ). From crystals grown in LCP, the OTR-retosiban complex structure was determined at 3.2 Å resolution with strong and unambiguous electron density for retosiban, cholesterol and key interaction residues of the receptor (Table 1 and Supplementary Figs. 1 and 2) .
Overall, OTR displays the canonical GPCR topology consisting of a seven transmembrane helical bundle (helices I-VII), two intracellular loops and three extracellular loops (ICLs and ECLs, respectively) and a C-terminal amphipathic helix VIII of which only the N-terminal part is resolved ( Fig. 1a,b ). Similar to other class A peptide GPCRs, the ECL2 of OTR forms an extended β-hairpin structure that is anchored to the extracellular tip of helix III by the conserved disulfide bridge between C112 3.25 and C187 of ECL2.
Ligand-Binding Pocket of OTR
Structural superpositions with other small-molecule bound GPCRs belonging to the β-branch of class A GPCRs reveal significant conformational differences at the extracellular helical ends of OTR, even though their overall root-mean-square deviations (RMSD) for backbone atoms are as low as 1.6 Å ( Supplementary Fig. 3 & Supplementary Table 1 ) 26,28-32 .
For the OTR, we find that the extracellular tips of helices II, III, V, VI and VII are moved away from the central axis of the hepta-helical bundle, with the most dramatic outward shifts observed for the extracellular ends of helices II, VI and VII ( Fig. 1c and Supplementary Fig. 3 ).
However, these extracellular conformational differences are not transferred to the intracellular side of the helical bundle since on this part of the receptor the helical conformations coincide with those of previously determined inactive peptidergic GPCR structures, consistent with the expectation that the OTR structure in complex with the antagonist retosiban is captured in the inactive state.
To quantify the consequences of the observed extracellular helical bundle expansion on the size of the solvent-accessible ligand binding pocket, we employed an analogous strategy as recently reported for the detailed analysis of the β1-adrenoceptor (β1-AR) 33 . We calculated the accessible volumes of the ligand binding sites of the different receptors (Supplementary Table 1 ), and from this analysis we find the OTR binding pocket volume to be enlarged by approximately 25% compared to other non-peptide antagonist-bound neuropeptide GPCRs.
Moreover, in comparison to the neurotensin receptor (NTS1R) in complex with its peptide agonist, the pocket volume of retosiban-bound OTR is increased by almost 50 %, in agreement with the reported contraction of the orthosteric pocket in the agonist-bound state of NTS1R 34 .
Overall, we find that the OTR binding pocket volume is most similar in size and shape to the previously reported exceptionally large binding site of the µ-opioid receptor (µ-OR) ( Fig. 1 , Supplementary Fig. 4 and Supplementary Table 1 ).
The increased size of the extracellular binding pocket of OTR may indicate the necessity to accommodate a cyclic peptide, a feature that is shared within the closely related oxytocin/vasopressin receptor family. Thus this feature may provide an opportunity in future drug discovery programs targeting these receptors.
Retosiban Binding Mode
Retosiban is a potent, non-peptide antagonist of OTR with >1400-fold selectivity over the closely related vasopressin receptors (V1a, V1b and V2) 35 . Chemically, retosiban ( Fig. 2a ) is composed of a central 2,5-diketopiperizine (2,5-DKP) core motif with three substituents at its 3, 6 and 7-positions (butan-2-yl, indanyl and 2′-methyl-1′,3′-oxazol-4′-yl morpholine amide, respectively) that were found to provide the best balance between potency and selectivity of all tested compounds 35, 36 .
Retosiban adopts an upright, elongated conformation along the central axis of the helical bundle with the indanyl located at the bottom, the 2,5-DKP core in a central position, the secbutyl substituent oriented towards helix V and the oxazol-morpholine amide moiety closest to the extracellular surface ( Fig. 2b,c) . Overall, the binding pocket can be divided into a polar interaction surface, created by a network of residues located on helices II to IV, and a largely hydrophobic hemisphere stretching from transmembrane helices V to VII ( Fig. 2e ).
The central 2,5-DKP core is found in a slightly kinked conformation with its 2-keto group pointing towards helix IV and the 5-keto group oriented towards helix VII. The 2,5-DKP core specifically interacts with the receptor through a polar interaction interface, which is formed by two glutamine (Q119 3.32 and Q171 4.60 ) and one lysine (K116 3.29 ) residue on the surface of helices III and IV on this side of the ligand binding pocket (Figs. 2a,b,e). Q171 4.60 forms a strong hydrogen bond (2.5 Å distance between sidechain nitrogen and ligand oxygen) with the 2-keto oxygen, while Q119 3.32 forms a weaker hydrogen bond with N1 of the 2,5-DKP core of retosiban (3.5 Å distance between sidechain oxygen and ligand nitrogen, Fig. 2a,b ). The critical contributions of these polar interactions for the high affinity binding of retosiban to the OTR are highlighted by a severe loss in binding affinity when K116 3.29 is mutated to alanine (75-fold), Q171 4.60 is mutated to alanine (1600-fold), and by a significant loss in binding affinity if either the length of the sidechain is varied (Q119 3.32 N, 12-fold) or if a negative charge (Q119 3.32 E, 440-fold) is introduced at position Q119 3.32 ( Fig. 2d and Supplementary Table 2 ).
The hydrophobic indanyl substituent attached at position 6 of the central 2,5-DKP core, which during initial structure-activity relationship (SAR) studies was shown to increase potency ∼15-fold 37 , optimally penetrates into a deep, mainly hydrophobic crevice at the bottom of the binding pocket, formed by sidechain residues of helices II, III, VI and VII. Within this pocketextension the indanyl is laterally sandwiched between Q92 2.57 and M123 3.36 and forms additional hydrophobic interactions with F291 6.51 , A318 7.42 and W288 6.48 (Fig. 2a,b ).
Additional interactions between OTR and retosiban are formed by the butan-2-yl substituent and the hydrophobic sidechains I201 5.39 , I204 5.42 and F291 6.51 on helices V and VI.
The importance of this hydrophobic interaction surface opposite to the polar network is underscored by a 214-fold loss in binding affinity of retosiban if F291 6.51 is mutated to alanine ( Fig. 2d and Supplementary Table 2 ). Higher up in the binding pocket, as part of the third, most solvent exposed substituent, the oxazol moiety is oriented towards I201 5.39 and is in close proximity to Q295 6.55 , while F175 4.64 provides an additional hydrophobic interaction with the amide linker to the morpholine ring. In line with the extensive SAR studies performed during the development of retosiban, the morpholine ring itself has no direct interactions with the receptor 36 .
Retosiban occupies a partially overlapping binding site at the bottom of the predicted orthosteric binding pocket. Importantly, retosiban directly interacts with residues Q92 2.57 , K116 3.29 , Q119 3.32 , Q171 4.60 and Q295 6.55 all of which were previously described to be part of the presumed orthosteric pocket of OTR based on structural studies performed on V1AR 38 . Of the eleven contact residues between retosiban and OTR all but I201 5.39 , I204 5.42 and A318 7.42 are conserved in the V1AR receptor (V217 5.39 , M220 5.42 and G337 7.42 in V1AR, respectively).
Interestingly, mutating A318 7.42 to its homologous amino acid glycine in V1AR has already previously been reported to influence the selectivity profile of other non-peptide OTR antagonists (L-371,257 and L-372,622) 39 . Thus, the high selectivity of retosiban for the OTR over the V1AR might at least be partially rationalized by these three non-conserved interaction residues in the OTR retosiban binding pocket.
Distinct Extrahelical Cholesterol Binding Site
Cholesterol is an abundant constituent of animal cell plasma membranes and has been shown to be intimately involved in the regulation of membrane proteins. This regulatory role of cholesterol can be achieved either indirectly by its ability to modulate the physical properties of the lipid bilayer (e.g. modulation of membrane fluidity, maintenance of lipid microdomains) or directly through specific protein-cholesterol interactions [40] [41] [42] . Modulation of protein function through cholesterol has previously been reported for a number of GPCRs including the OTR 23,43,44 , and multiple class A GPCR crystal structures have revealed direct structural evidence for specific cholesterol-GPCR interactions [45] [46] [47] , albeit at different locations in the structures.
In particular the physiological function as well as the thermostability of the OTR have been shown to be critically dependent on the presence of cholesterol. Importantly, these findings provided evidence that cholesterol or its analogues act as allosteric modulators of the OTR by shifting the receptor to a high-affinity state for both agonist and antagonist binding 23, 43, 48 . However, despite extensive efforts, no specific cholesterol binding site has been identified for the OTR to date.
The structure of the OTR-retosiban complex displays unambiguous extrahelical electron density for one molecule of cholesterol in a distinct extrahelical surface groove that is formed by hydrophobic residues of helices IV and V and is capped towards the extracellular space by residues of ECL2 (Fig. 3a) .
The steroid core of cholesterol specifically contacts the receptor through main hydrophobic interactions with the highly conserved (within the oxytotocin/vasopressin receptor family) residues Y200 5.38 and W203 5.41 (Supplementary Fig. 5 ) of helix V, and further with the more distal residues P170 4.59 and I174 4.63 on Helix IV, residues V190, F191 and W295, all of ECL2, as well as residues G196 5.43 and A199 5.37 on Helix V (Fig. 3b ). Additionally to these hydrophobic interactions, cholesterol forms a hydrogen bond to the backbone amide of residue I192 of ECL2 with its β3-hydroxyl group.
To probe whether the observed cholesterol interaction is indeed critical for the integrity and stability of OTR, we characterised the thermal stability of purified, detergent-solubilised receptor and several mutants in the presence or absence of the cholesterol analogue cholesteryl hemisuccinate (CHS). We monitored protein unfolding using the previously described 7diethylamino-3-(4-maleimidophenyl)-4-methylcoumarin (CPM)-based thermal shift assay 49 ( Fig. 3d ). Since wtOTR could not be purified, due to very low expression yields and insufficient thermostability, the thermal stability analyses were performed with OTRXTAL or mutants thereof.
In accordance with previous findings 48 , the stability of OTRXTAL is significantly impaired in DDM in the absence of CHS, as evidenced by a decrease of 12°C in thermostability, when compared to the same construct measured in DDM supplemented with CHS ( Fig. 3d and Supplementary Table 4 ). A similar effect has also been reported for several other GPCRs [50] [51] [52] [53] .
To test the individual contributions of residues within the observed cholesterol binding site, we next expressed and purified OTRXTAL mutants where the two most prominent aromatic residues within the cholesterol binding site, Y200 5.38 and W203 5.41 , were each mutated to alanine.
In the absence of CHS, OTRXTAL and the two mutants Y200 5.38 A and W203 5.41 A display comparable melting temperatures (43.7°C, 44.5°C and 41.9°C, respectively), indicating a similar limited stability of all three receptor variants ( Fig. 3d and Supplementary Table 4 ). This similarity of melting temperatures of OTRXTAL mutants and OTRXTAL wt shows that there is no strongly destabilising effect of the introduced mutations themselves. In the presence of CHS, in contrast, all three variants are stabilised as evidenced by higher melting temperatures, albeit to varying extents (Fig. 3d ). The two tested OTRXTAL mutants, where key cholesterolinteracting residues were exchanged to alanine, display a significant decrease in thermostability of 9°C (Y200 5.38 A) and 3°C (W203 5.41 A) in comparison to OTRXTAL, when CHS is present.
This observed decrease in thermal stability of the mutants can be best rationalised by the perturbation and weakening of the binding of CHS to the cholesterol binding pocket.
To further validate the biological relevance of the observed cholesterol binding site and delineate its influence on antagonist and agonist binding in a native lipid environment, we generated point mutants of Y200 5.38 and W203 5.41 in the background of wtOTR and probed their involvement in cholesterol binding to the OTR in a cell-based assay. Y200 5.38 and W203 5.41 were individually mutated to either alanine or histidine and ligand binding was assessed using a homogeneous time-resolved fluorescence (HTRF)-based assay 54 . This experimental setup allowed us to measure simultaneously total receptor surface expression levels through the donor-only signal (E620) originating from the fluorescently labelled SNAP-tag and the maximum attainable response Bmax (E665/E620) (as a measure of functional protein) at saturating concentrations of a fluorescently labelled agonist or antagonist (see Methods for details).
While all tested mutants displayed total surface expression levels similar to the wtOTR (Fig. 3e ), the measured Bmax values of the respective mutants were dramatically reduced in comparison to the wild-type receptor (Figs. 3f,g) . The strong reduction in the Bmax values suggest that, although wtOTR and the respective mutants are expressed and localised in equivalent amounts on the cellular surface, upon mutation of residues involved in the cholesterol-interaction, only a fraction of receptors remains functional with regard to both agonist and antagonist binding. Therefore, also in a native environment the mutations introduced in the cholesterol binding site appear to have a detrimental effect on the structural integrity of the extracellular binding pocket itself, with direct consequences for agonist as well as antagonist binding.
Mechanistically, the receptor modulation by the presence of cholesterol in this particular binding site might occur through the direct interaction with ECL2, which has been reported to be intimately involved in agonist binding 55 . However, cholesterol appears to also directly influence the polar network of the ligand binding pocket through the positioning of Y200 5.38 , which can then form a hydrogen bond with the carbonyl side chain of Q171 4.60 and thereby optimally orient this residue within the extracellular binding cavity (Fig. 3c) , thereby rendering the OTR in a state for optimal ligand recognition and interaction -the aforementioned highaffinity state.
Allosteric Divalent Cation Coordination Site
GPCRs are intrinsically allosteric molecules, with many of them being negatively modulated by the monovalent cation Na + . High-resolution structures of several receptors have provided a structural basis for this observation: an interhelical Na + binding site within the conserved water-mediated hydrogen bond network connecting helices II, III, VI and VII stabilises the inactive receptor conformation in the presence of Na + and leads to a measurable decrease in agonist affinity 56 . Also for the OTR, Na + has been shown to act as a negative allosteric modulator with the sodium binding pocket located in the aforementioned network in the core of the receptor 57 . In contrast to the negative allosteric effect of monovalent sodium ions, divalent cations such as Mg 2+ (but also Ni 2+ , Zn 2+ , Mn 2+ and Co 2+ ) were shown to act as positive allosteric modulators of the OTR 24,58-60 .
In the antagonist-bound OTR structure we discovered two acidic amino acids, E42 1.35 and D100 2.65 , located at the extracellular tips of helices I and II, which are found in unusually close proximity to each other (Fig. 4a ). Both residues have previously been described to be involved in the binding of endogenous cyclic peptide agonists (E42 1.35 in OTR for oxytocin binding; and both corresponding residues, E37 1.35 and D95 2.65 in V1AR, for AVP binding 61, 62 . The short distance of only 2.8 Å between the closest oxygens of the carboxyl head groups of these two amino acids in the antagonist-bound state suggests that in this arrangement in the determined structure, the two residues share a proton. We hypothesised that, based on the charged nature and close proximity of these residues to the presumed orthosteric binding site of the OTR, this region might represent the elusive coordination site for divalent cations, known to be involved in modulating neurohypophyseal hormone binding. We note, however, that in the captured antagonist-bound state no divalent cation could be observed.
Initial amino acid sequence alignments across both the OTR and the related V1AR
sequences revealed that this region of transmembrane helices I and II is highly conserved in both receptors across mammalian species ( Fig. 4b and Supplementary Table 4 ). Since the evolutionary lineage of disulfide-linked oxytocin-and vasopressin-related hormones, and thus possibly their associated GPCRs, existed for at least 700 million years 1 , we next expanded our search to receptor homologues identified in more distant taxa such as non-mammalian vertebrates and invertebrates. Indeed, we find that the glutamate in helix I and the aspartate in helix II as well as surrounding residues are strictly conserved there as well and might thus represent a mechanistically critical motif for the function of these GPCRs. Moreover, sequence comparisons with closely related class A GPCRs binding to linear peptides (Supplementary To test if the acidic residues of helices I and II are indeed involved in the positive allosteric modulation of agonist binding through divalent cation coordination, we measured the binding affinity of fluorescently labelled oxytocin (HiLyte Fluor 488-Orn 8 oxytocin) in the presence or absence of Mg 2+ , which is most likely the physiologically relevant cation 54 , with an HTRF-based assay. We used HEK293T cells expressing either the wtOTR, one of the single point mutants E42 1.35 A and D100 2.65 A, or the double mutant E42 1.35 D/D100 2.65 E ( Fig. 4c and Supplementary Table 5 ). In accordance with previous studies which reported a pronounced influence of magnesium on the binding of different agonists to OTR 57, 58 we observed a 30-fold increase in affinity for oxytocin to the wild-type receptor in the presence of 3 mM Mg 2+ , compared to the same experiment performed in its absence. When divalent cations were depleted through addition of ethylenediaminetetraacetic acid (EDTA), the affinity for oxytocin to all three evaluated mutants as well as wtOTR was found to be very similar (Supplementary Table 5 ).
In contrast, in the presence of 3 mM Mg 2+ , the individual substitution of either E42 1.35 or D100 2.65 by alanine abolishes the positive modulatory effect of Mg 2+ on oxytocin binding, thus highlighting the importance of these two specific residues in divalent cation binding.
Importantly , under the same experimental conditions, the positive allosteric effect of Mg 2+ can only be partly restored by interchanging residues, E42 1.35 D and D100 2.65 E, suggesting a significant influence of the precise spatial orientation of these two acidic residues and participation of further Mg 2+ -liganding atoms from the agonist and receptor, which is supported by the strong conservation of surrounding residues.
Taken together, these results strongly suggest that E42 1.35 and D100 2.65 constitute part of the physiologically important coordination site of the OTR for divalent cations and presumably also in the closely related vasopressin receptors, and that the precise spatial orientation of these residues is critical for high-affinity binding of the cyclic peptide agonists of these receptors.
Discussion
Due to their distinct roles in social behaviour, cognition and reproduction 7 , the receptors of the oxytocin and vasopressin family represent attractive drug targets. The crystal structure of the OTR in complex with the small-molecule antagonist retosiban presented in this study provides the first structural insights into these distinct neuropeptide GPCRs; it furthermore allows us to provide answers to several long-standing questions regarding the structural basis of the essential modulatory effects by both cholesterol and divalent cations. Both of these can likely be extrapolated to the closely related vasopressin receptors due to their high sequence conservation.
The solvent-exposed binding pocket of retosiban-bound OTR is significantly larger in comparison to other antagonist-bound peptidergic GPCRs, which is possibly a direct consequence of the requirement to accommodate a cyclic nonapeptide agonist. Within the binding pocket the ligand-accessible interface, ranging from helix II to helix IV, is dominated by a polar network, while the opposing side of the cavity is largely hydrophobic. By virtue of its 2,5-diketopiperizine core and its chemically diverse substituents, the co-crystallised nonpeptide oral antagonist retosiban optimally addresses this challenging environment, lending credit to decades of SAR studies to optimise such compounds.
Additionally, the OTR structure provides new structural insights into the binding location of the modulatory cholesterol molecule. We find that the cholesterol molecule binds to an extrahelical crevice (formed between helices IV, V and ECL2) that is distal from previously reported cholesterol interaction sites on other GPCRs, consistent with non-conserved sequences in these regions 47 . Through mutagenesis experiments using orthogonal assays we established that binding of cholesterol in OTR is critically governed by the conserved aromatic residues Finally, a mechanistic basis of the allosteric modulation of OTR function through interaction with Mg 2+ is provided by the identification of an evolutionarily highly conserved Mg 2+ binding site which is formed by two acidic residues at the extracellular tips of helices I and II, likely involving other coordinating atoms in agonist and receptor. To our knowledge, the identification and verification of this distinct, solvent-exposed coordination site in the OTR represents the first example for a positive allosteric modulatory mechanism of GPCRs by divalent cations and thus further expands our knowledge of this intrinsically allosteric receptor superfamily.
Despite their diverse physiological roles, the receptors for the cyclic peptide hormones oxytocin and vasopressin are very closely related. Thus, the studies presented here provide not only answers concerning the OTR itself, but these findings will support research advances within the vasopressin receptors, or possibly can even be directly extrapolated. We anticipate that the inaugural structure from this medically highly relevant receptor family branch opens up attractive possibilities to deploy structure-based drug-design methods to not only the OTR but eventually also to the vasopressin receptors in an effort to develop new therapeutics for the efficient treatments of a diverse and important array of diseases.
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Methods
Generation of OTR crystallisation construct
The human OTR gene was codon-optimised for Spodoptera frugiperda (Sf9) expression, synthesised (Integrated DNA Technologies) and cloned into a modified pFL vector (MultiBac system, Geneva Biotech) resulting in an expression construct with an N-terminal melittin signal sequence followed by a FLAG-tag, His10-tag and a human rhinovirus 3C protease cleavage site.
In the crystallisation construct, several modifications were introduced to the receptor to increase the functional expression yield, stability and crystallisation: To aid crystal contact formation in lipidic cubic phase 34 residues (R232-L265) of the ICL3 were replaced by the thermostable Pyrococcus abysii glycogen synthase (PGS) domain and 30 residues (360-389) were truncated from the C-terminus of the receptor. Analogous to previously reported structures, the gene was further modified by introducing mutations to improve protein yield and thermostability: A19T, R65H, V120L, A167V, Q193R, S322C, N325K and T333M were selected through two consecutive rounds of directed evolution in yeast 25 on the wtOTR using the fluorescently labelled peptide antagonist PVA 63 (HiLyte Fluor 647-Lys 8 PVA (Eurogentec)), while D153A and S224A were identified to further increase thermostability as evidenced by an increase in melting temperature (Tm) in the CPM assay 49 .
For ligand-binding experiments, the codon-optimised wtOTR gene was subcloned into a mammalian expression vector (pcDNA3.1(+)) containing an N-terminal SNAP-tag (Cisbio).
Point mutations were derived from this construct using SLIC cloning 64 .
Expression and purification of OTR
Recombinant baculovirus was generated using the MultiBac expression system. The receptor expression was performed as previously described 30 . Briefly, Spodoptera frugiperda (Sf9) insect cells were infected with high-titer P1 or P2 baculovirus stocks (multiplicity of infection 20 °C; however, for optimal crystal growth and diffraction the screening plates were subsequently transferred to a humidified incubator set to 16 °C. Optimised crystals used for data collection of retosiban-bound OTR were obtained in a condition consisting of 100 mM N- Data from the nine best diffracting crystals were merged and scaled using the program AIMLESS from the CCP4 suite 66, 67 . Data collection statistics are reported in Table 1 .
Initial phase information was obtained by molecular replacement (MR) with the program Phaser 68 using a truncated poly-alanine model of the OX1R transmembrane domain (PDB ID 4ZJ8) and the separated PGS fusion protein 26 as independent search models looking for one copy of each domain. Manual model building was performed in COOT 69 using sigma-A weighted 2m|Fo|-|DFc|, m|Fo|-D|Fc| maps together with simulated-annealing and simple composite omit maps calculated using Phenix 70 . Initial refinement was carried out with REFMAC5 71 using maximum-likelihood restrained refinement in combination with the jellybody protocol. Further and final stages of refinement were performed with Phenix.refine 72 with positional, individual isotropic B-factor refinement and TLS. The final refinement statistics are presented in Table 1 . Co-ordinates and structure factors have been deposited in the Protein Data M1000 fluorescence plate reader (Tecan) with an excitation wavelength of 340 nm. Acceptor emission was measured at 520 nm or 665 nm for the HiLyte Fluor 488 or 647, respectively. The Tb 3+ donor emission was recorded at 620 nm. The ratio of FRET-donor and acceptor fluorescence intensities was calculated (F665 nm/F520 nm or F620 nm). Total binding was obtained in the absence of competitor, and nonspecific binding was determined in the presence 
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